# Camp4 Therapeutics Corp (CAMP) — capital_raise/private_placement [pending]
Source: SEC API (secapi.ai) · situation sit_c34708bad6265452093f · retrieved 2026-08-11T16:15:10.667Z

## Overview
Camp4 Therapeutics Corporation is a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression to treat genetic diseases, with its lead candidate CMP-002 targeting SYNGAP1-related disorder.

Camp4 Therapeutics Corporation completed the second closing of its private placement on August 3, 2026, issuing 10,756,498 common shares at $1.53 per share and 21,925,368 pre-funded warrants at $1.5299 per warrant. The company also issued 39,306 common shares to management and co-founders at $1.65 per share. The second closing generated approximately $50.1 million in gross proceeds. The pre-funded warrants have an exercise price of $0.0001 per share, are exercisable on a cashless basis, and are subject to a 19.99% beneficial ownership limitation. The second closing was triggered by the company's receipt of clearance from Australia's Therapeutic Goods Administration to initiate a Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder, combined with a price threshold waiver from certain investors.

## Terms
- Counterparty: Coastlands Capital, Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management LP, Trails Edge Capital Partners, and CURE SYNGAP1 · Deal value: $50.1M · Consideration: mixed · Price/share: $1.53

## Key dates
- Announced 2026-07-27 · Expected close 2026-08-03

## Timeline
- 2026-07-27 · 8-K (0001628280-26-049661): 8-K - Camp4 Therapeutics Corp — *Camp4 Therapeutics is a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics designed to upregulate gene expression to treat genetic diseases, with CMP-002 as its lead investigational candidate for SYNGAP1-related disorder.* Camp4 Therapeutics announced on July 27, 2026 that it received regulatory clearance from Australia's Therapeutic Goods Administration and local Human Research Ethics Committee to initiate a Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder. This clearance satisfied the CTA Milestone under the company's September 9, 2025 Securities Purchase Agreement, triggering the Second Closing. The company is eligible to receive up to approximately $50.1 million in gross proceeds in exchange for up to 32,721,172 shares of common stock (or pre-funded warrants for certain investors). The Second Closing is expected to occur on or about August 3, 2026, subject to customary closing conditions. Committed investors include Coastlands Capital, Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management LP, Trails Edge Capital Partners, and CURE SYNGAP1.
  https://www.sec.gov/Archives/edgar/data/1736730/0001628280-26-049661.txt
- 2026-08-04 · 8-K (0001628280-26-052150): 8-K - Camp4 Therapeutics Corp — *Camp4 Therapeutics Corporation is a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression to treat genetic diseases, with its lead candidate CMP-002 targeting SYNGAP1-related disorder.* Camp4 Therapeutics Corporation completed the second closing of its private placement on August 3, 2026, issuing 10,756,498 common shares at $1.53 per share and 21,925,368 pre-funded warrants at $1.5299 per warrant. The company also issued 39,306 common shares to management and co-founders at $1.65 per share. The second closing generated approximately $50.1 million in gross proceeds. The pre-funded warrants have an exercise price of $0.0001 per share, are exercisable on a cashless basis, and are subject to a 19.99% beneficial ownership limitation. The second closing was triggered by the company's receipt of clearance from Australia's Therapeutic Goods Administration to initiate a Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder, combined with a price threshold waiver from certain investors.
  https://www.sec.gov/Archives/edgar/data/1736730/0001628280-26-052150.txt

## Citations
- 0001628280-26-049661 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000162828026049661
- 0001628280-26-052150 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000162828026052150